Lin Gan
Guiyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Metabolic and Immunological Trajectories and Virological Outcomes of Ainuovirine-Based Antiretroviral Therapy: A 48-Week Longitudinal Cohort Study in Treatment-Naïve Adults.
Journal: Journal of medical virology
Published: December 30, 2025
A machine learning model for predicting adverse prognostic events in patients with neurosyphilis: Results from the DEFEAT-NS study.
Journal: iScience
Published: October 28, 2025
Safety, pharmacokinetics, and efficacy of albuvirtide administered by intravenous bolus every 4 weeks in combination with oral dolutegravir in virologically suppressed adults living with HIV: A 24-week study.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: September 24, 2025
Efficacy and safety of dolutegravir plus lamivudine for patients with late presentation of HIV-1 infection: a retrospective real-world cohort study in Southwest China.
Journal: Frontiers in medicine
Published: May 19, 2025
Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV-Infected Individuals in Southwest China: A Retrospective Observation Study.
Journal: Immunity, inflammation and disease
Published: December 24, 2024
Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed HIV-1 adults: a 24-week study.
Journal: AIDS (London, England)
Published: October 21, 2024
Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Late-Presenting People With HIV-1 Infection.
Journal: Open forum infectious diseases
Published: July 31, 2024
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
Journal: Expert review of anti-infective therapy
Published: December 07, 2023
Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Journal: BMC infectious diseases
Published: November 23, 2023
Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.
Journal: Expert review of anti-infective therapy
Published: November 06, 2023
Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study.
Journal: Immunity, inflammation and disease
Published: September 22, 2023
Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study.
Journal: Infectious diseases and therapy
Published: July 10, 2023
Last Updated: 09/26/2026